S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Wall Street inches lower as retailers post holiday numbers
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
Ohio foundation begins process to distribute millions in opioid settlement money
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Wall Street inches lower as retailers post holiday numbers
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
Ohio foundation begins process to distribute millions in opioid settlement money
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Wall Street inches lower as retailers post holiday numbers
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
Ohio foundation begins process to distribute millions in opioid settlement money
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Wall Street inches lower as retailers post holiday numbers
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
Ohio foundation begins process to distribute millions in opioid settlement money
NASDAQ:HZNP

Horizon Therapeutics Public (HZNP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$116.30
$116.30
50-Day Range
$112.60
$116.30
52-Week Range
$60.03
$116.38
Volume
N/A
Average Volume
2.50 million shs
Market Capitalization
$26.63 billion
P/E Ratio
62.19
Dividend Yield
N/A
Price Target
N/A

HZNP stock logo

About Horizon Therapeutics Public Stock (NASDAQ:HZNP)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.


HZNP Stock News Headlines

5 Biotech Acquisition Targets To Accumulate In 2024
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Rule 17(e) Announcement - Horizon Therapeutics plc
Rule 17(d) Announcement - Horizon Therapeutics plc
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Rule 17(d) Announcement – Horizon Therapeutics plc
Improved Outlook For Horizon Therapeutics And Amgen
Horizon Therapeutics (HZNP) Receives a Hold from H.C. Wainwright
See More Headlines
Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:HZNP
CUSIP
44047T10
Employees
2,115
Year Founded
2008

Profitability

Net Income
$521.48 million
Pretax Margin
12.18%

Debt

Sales & Book Value

Annual Sales
$3.63 billion
Cash Flow
$7.05 per share
Book Value
$22.38 per share

Miscellaneous

Free Float
223,957,000
Market Cap
$26.63 billion
Optionable
Optionable
Beta
1.03

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Should I Buy Horizon Therapeutics Public Stock? HZNP Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Horizon Therapeutics Public was last updated on Friday, March 1, 2024 at 1:56 PM.

Pros

Here are some ways that investors could benefit from investing in Horizon Therapeutics Public Limited:

  • Horizon Therapeutics has a diverse portfolio of 12 medicines targeting rare diseases, gout, ophthalmology, and inflammation, providing a wide revenue stream.
  • The company has collaboration agreements with various biopharmaceutical companies, enhancing its research and development capabilities.
  • Recent stock holdings by Tokio Marine Asset Management Co. Ltd. indicate investor confidence in the company's growth potential.
  • Horizon Therapeutics focuses on addressing critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases, showing a commitment to societal impact.
  • The company's name change in 2019 to Horizon Therapeutics Public Limited reflects a strategic rebranding effort, potentially signaling positive transformations within the organization.

Cons

Investors should be bearish about investing in Horizon Therapeutics Public Limited for these reasons:

  • The pharmaceutical industry is highly competitive and subject to regulatory challenges, impacting the company's product development and market access.
  • Market volatility and economic uncertainties can affect the demand for pharmaceutical products, potentially impacting Horizon Therapeutics' revenue streams.
  • Dependency on a few key products like TEPEZZA, KRYSTEXXA, and RAVICTI for a significant portion of revenue poses risks in case of market shifts or patent expirations.
  • Collaboration agreements with other companies may introduce complexities in decision-making processes and could lead to conflicts of interest.
  • Investing in pharmaceutical companies involves inherent risks related to clinical trial outcomes, regulatory approvals, and market acceptance of new drugs, which can impact financial performance.














HZNP Stock Analysis - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings
or view top-rated stocks.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) released its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.08. The biopharmaceutical company had revenue of $945 million for the quarter, compared to the consensus estimate of $873.52 million. Horizon Therapeutics Public had a net margin of 12.02% and a trailing twelve-month return on equity of 20.46%. The firm's quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.07 EPS.

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Highbridge Capital Management LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%), Picton Mahoney Asset Management (0.00%), BCK Capital Management LP (0.00%), Simplex Trading LLC (0.00%) and Equitec Proprietary Markets LLC (0.00%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert and William F Daniel.
View institutional ownership trends
.

Does Horizon Therapeutics Public have any subsidiaries?
The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..
Read More
This page (NASDAQ:HZNP) was last updated on 3/5/2024 by MarketBeat.com Staff